Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th
23 mai 2022 16h05 HE
|
Immunovant
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant to Present at the UBS Global Healthcare Conference on May 23rd
19 mai 2022 16h05 HE
|
Immunovant
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th
04 mai 2022 08h00 HE
|
Immunovant
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant to Host Virtual R&D Day on March 30, 2022
28 mars 2022 07h00 HE
|
Immunovant
NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference
09 févr. 2022 08h00 HE
|
Immunovant
NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant Reports Financial Results for the Quarter Ended December 31, 2021
04 févr. 2022 07h00 HE
|
Immunovant
NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant Appoints Mark Levine as Chief Legal Officer
25 janv. 2022 08h30 HE
|
Immunovant
Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25,...
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
07 janv. 2022 14h07 HE
|
Immunovant
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
30 déc. 2021 07h00 HE
|
Immunovant
NEW YORK, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases,...
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
12 nov. 2021 12h18 HE
|
Immunovant
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...